DEXMEDETOMIDINE KABI INJECTION 100MCG/ML

Product Information

Registration Status: Active

DEXMEDETOMIDINE KABI INJECTION 100MCG/ML is approved to be sold in Singapore with effective from 2017-06-12. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN15269P.

This product contains Dexmedetomidine 100mcg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.

This product is manufactured by GLAND PHARMA LTD in INDIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Dexmedetomidine

Description

An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]

Indication

For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia

Mechanism of Action

Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.

Clearance

* 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]

Active Ingredient/Synonyms

(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole | (+)-medetomidine | (S)-medetomidine | Dexmedetomidin | Dexmedetomidina | Dexmédétomidine | Dexmedetomidinum | Dexmedetomidine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank